References
- Aucott SW, Donohue PK, Northington FJ. Increased morbidity in severe early intrauterine growth restriction. J Perinatol 2004; 24: 435–440
- Baschat AA. Arterial and venous Doppler in the diagnosis and management of early onset fetal growth restriction. Early Hum Dev 2005; 81: 877–887
- Sieroszewski P, Suzin J, Karowicz-Bilinska A. Ultrasound evaluation of intrauterine growth restriction therapy by a nitric oxide donor (l-arginine). J Matern Fetal Neonatal Med 2004; 15: 363–366
- Takagi Y, Nikaido T, Toki T, Kita N, Kanai M, Ashida T, Ohira S, Ohira S, Konishi I. Levels of oxidative stress and redox-related molecules in the placenta in preeclampsia and fetal growth restriction. Virchows Arch 2004; 444: 49–55
- Longini M, Perrone S, Kenanidis A, Vezzosi P, Marzocchi B, Petraglia F, Centini G, Buonocore G. Isoprostanes in amniotic fluid: A predictive marker for fetal growth restriction in pregnancy. Free Radic Biol Med 2005; 38: 1537–1541
- Vosatka RJ, Hassoun PM, Harvey-Wilkes KB. Dietary l-arginine prevents fetal growth restriction in rats. Am J Obstet Gynecol 1998; 178: 242–246
- Xiao XM, Li LP. l-Arginine treatment for asymmetric fetal growth restriction. Int J Gynaecol Obstet 2005; 88: 15–18
- Galao AO, Pinheiro da Costa BE, d'Avila DO, Poli de Figueiredo CE. l-Arginine erythrocyte transport increases during pregnancy and immediately postpartum. Am J Obstet Gynecol 2004; 191: 572–575
- da Costa BP, Steibel JP, Antonello IC, Guimaraes JA, Poli de Figueiredo CE. l-Arginine erythrocyte transport in normal pregnant and preeclamptic women. Am J Obstet Gynecol 2004; 190: 468–471
- Rytlewski K, Olszanecki R, Lauterbach R, Grzyb A, Basta A. Effects of oral l-arginine on the foetal condition and neonatal outcome in preeclampsia: A preliminary report. Basic Clin Pharmacol Toxicol 2006; 99: 146–152
- Chiueh CC. Neuroprotective properties of nitric oxide. Ann N Y Acad Sci 1999; 890: 301–311
- Mohanakumar KP, Thomas B, Sharma SM, Muralikrishnan D, Chowdhury R, Chiueh CC. Nitric oxide: An antioxidant and neuroprotector. Ann N Y Acad Sci 2002; 962: 389–401
- Hummel SG, Fischer AJ, Martin SM, Schafer FQ, Buettner GR. Nitric oxide as a cellular antioxidant: A little goes a long way. Free Radic Biol Med 2006; 40: 501–506
- Gewaltig MT, Kojda G. Vasoprotection by nitric oxide: Mechanisms and therapeutic potential. Cardiovasc Res 2002; 55: 250–260
- Faraci FM. Reactive oxygen species: Influence on cerebral vascular tone. J Appl Physiol 2006; 100: 739–743
- Waugh JM, Li-Hawkins J, Yuksel E. Therapeutic elastase inhibition by alpha-1-antitripsin gene transfer limits neointima formation. J Vasc Interv Radiol 2001; 12: 1203–1209
- Ueda M, Mashiba S, Uchida K. Evaluation of oxidized alpha-1-antitrypsin in blood as an oxidative stress marker using anti-oxidative alpha1-AT monoclonal antibody. Clin Chim Acta 2002; 317: 125–131
- Starosta V, Griese M. Protein oxidation by chronic pulmonary diseases in children. Pediatr Pulmonol 2006; 41: 67–73
- Biondi C, Pavan B, Lunghi L, Fiorini S, Vesce F. The role and modulation of the oxidative balance in pregnancy. Curr Pharm Des 2005; 11: 2075–2089
- Agarwal A, Gupta S, Sikka S. The role of free radicals and antioxidants in reproduction. Curr Opin Obstet Gynecol 2006; 18: 325–332
- Karowicz-Bilinska A, Marszalek M, Kowalska-Koprek U, Suzin J, Sieroszewski P. Plasma carbonyl group concentration in pregnant women with IUGR treated by l-arginine and acetylsalicylic acid. Ginekol Pol 2004; 75: 15–20
- Karowicz-Bilinska A. Lipid peroxides concentration in women with intrauterine growth restriction. Ginekol Pol 2004; 75: 6–9
- Nishino F, Takagi T, Mitsuda N, Masihiro K, Iwata M, Tanizawa O. Effect of low-dose aspirin therapy on utero-placental blood flow and malondialdehyde (MDA) as an indicator of it's therapeutic effect. Nippon Sanka Fujinka Gakkai Zasshi 1990; 42: 1641–1647
- Neely MD, Amarnath V, Weitlauf C, Montine TJ. Synthesis and cellular effects of an intracellularly activated analogue of 4-hydroxynonenal. Chem Res Toxicol 2002; 15: 40–47
- Petersen DR, Doorn JA. Reactions of 4-hydroxynonenal with proteins and cellular targets. Free Radic Biol Med 2004; 37: 937–945
- Ishii T, Kumazawa S, Sakurai T, Nakayama T, Uchida K. Mass spectroscopic characterization of protein modification by malondialdehyde. Chem Res Toxicol 2006; 19: 122–129
- Watanabe T, Pakala R, Katagiri T, Benedict CR. Lipid peroxidation product 4-hydroxy-2-nonenal acts synergistically with serotonin in inducting vascular smooth muscle cell proliferation. Atherosclerosis 2001; 155: 37–44
- Aldonyte R, Jansson L, Ljungberg O, Larsson S, Janciauskiene S. Polymerized alpha-antitrypsin is present on lung vascular endothelium. New insights into the biological significance of alpha-antitrypsin polymerization. Histopathology 2004; 45: 587–592
- Blanco LE, de Serres FJ, Fernandes-Bustillo E, Kassam DA, Arbesu D, Rodrigues C, Torre JC. Alpha-1-antitripsin and fibromyoalgia: New data in favour of the inflammatory hypothesis of fibromyoalgia. Med Hypotheses 2005; 64: 759–769
- Werler MM, Mitchell AA, Shapiro S. The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects. N Engl J Med 1989; 321: 1639–1642
- Li DK, Liu L, Odouli R. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: Population based cohort study. BMJ 2003; 327: 368
- Karowicz-Bilinska A, Suzin J, Sieroszewski P. Evaluation of oxidative stress indices during treatment in pregnant women with intrauterine growth retardation. Med Sci Monit 2002; 8: CR211–CR216
- Karowicz-Bilińska A, Suzin J, Kowalska-Koprek U, Sieroszewski P. Intrauterine growth restriction treatment by l-arginine (and aspirine). Clinical and biochemical results. Klin Perinatol Ginekol 2004; 40: 3–7